%0 Journal Article
%T Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
%A Giou-Teng Yiang
%A Horng-Jyh Harn
%A Yung-Luen Yu
%A Sheng-Chuan Hu
%A Yu-Ting Hung
%A Chia-Jung Hsieh
%A Shinn-Zong Lin
%A Chyou-Wei Wei
%J Journal of Biomedical Science
%D 2009
%I BioMed Central
%R 10.1186/1423-0127-16-47
%X There had been many studies that considered immunotherapy as a potent method for the treatment of cancer and this method inhibits tumor growth [1,2]. Both interleukin-2 (IL2) and interleukin-15 (IL15) have been used for cancer immunotherapy [3,4]. However, previous studies indicated that IL2 displayed a significant toxicity in immunotherapy after systemic administration of high-dose IL2 [5,6]. IL15 is a 14¨C15 Kd immunostimulatory cytokine which belongs to a four ¦Á-helix cytokine family [7,8]. Using IL15 for cancer immunotherapy based on NK cell activity and immunoglobulin production had been demonstrated previously [9,10]. Repeated daily injection is required because of the short biological half-life using IL15 administration [11-13]. In addition, some studies showed that tumor cells engineered to secrete IL15 can inhibit tumor growth on animal models [6,14]. That would suggest that replacing daily administration using gene therapy may be useful for cancer immunotherapy. Recently, a study demonstrated that an adenovirus vector expressing IL15 gene can inhibit lung cancer in mouse [15]. However, adenovirus vector is not suitable for human gene therapy due to its cytoxicity and inflammatory response [16]. Hence this study used a safer viral vector (rAAV2) expressing hIL15 for human cervical cancer treatment.Many studies have demonstrated that rAAV2 is a good choice for gene therapy because of the attractive features offered by this gene delivery system. The major advantages of rAAV2's are nonpathogenic in human with low immunogenicity compared with the other viral delivery systems [17,18]. Moreover, rAAV2s can infect both the dividing and quiescent cells by inducing a long-term stable gene expression in a wide variety of tissues [19-21]. Recently, rAAV2 has been demonstrated safe in human clinical trails [22,23]. Based on these attractive features, we chose rAAV2 delivery system to express hIL15 for cancer immunotherapy.Previous study has indicated that rAAV2 vector i
%U http://www.jbiomedsci.com/content/16/1/47